JPRN-UMIN000007803
Recruiting
Phase 2
The efficacy and safety of subcutaneous injection of bortezomib combined with doxorubicin and dexamethasone for untreated multiple myeloma patients. - The efficacy and safety of sPAD
ational Hospital Organization Disaster Medical Center0 sites35 target enrollmentApril 21, 2012
Conditionsmultiple myeloma
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- multiple myeloma
- Sponsor
- ational Hospital Organization Disaster Medical Center
- Enrollment
- 35
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •The exclusion criteria were a serum creatinine level\>2\.05 mg/dL, liver dysfunction (e.g., a serum total bilirubin level\>2\.0 mg/dL, or serum aspartate/alanine aminotransferase or alkaline phosphatase levels more than 2\.5 times the upper limit of normal), grade 3 or worse peripheral neuropathy, significant comorbidity that would preclude ASCT, poor performance status (\>grade 3\), and a history of any other malignancy with the exception of basal cell carcinoma and stage I cervical cancer.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Efficacy and Safety of subcutaneous administration of XM01 and Epoetin beta for treatment of anaemia in chronic renal failure patients not yet receiving dialysis. A multinational, multicentre, randomised, controlled, double-blind, parallel group phase II study.EUCTR2005-000140-85-HUBioGeneriX AG150
Active, not recruiting
Not Applicable
Efficacy and Safety of subcutaneous administration of XM01 compared to Epoetin beta in anaemic chronic renal failure patients not yet receiving dialysis and in maintenance phase treatment with Epoetin beta. A multinational, multicentre, randomised, controlled, double-blind, comparative, parallel group Phase III study.anaemic chronic renal failure patients not yet receiving dialysisMedDRA version: 9Level: LLTClassification code 10009119EUCTR2005-000142-37-HUBioGeneriX AG255
Completed
Phase 4
Efficacy and Safety of Subcutaneous Administration of Lyophilized Powder of Alpha-Erythropoietin to Maintains Hemoglobin Concentrations among Hemodialysis PatientsAnemia associated with chronic kidney diseaseAnemiaHemodialysisLyophilised powderErythropoietinTCTR20161214001Phramongkutklao hospital and College of Medicine63
Active, not recruiting
Phase 1
Safety and efficacy of subcutaneous (SC) administration of Clinimix N9G15E in elderly patients at risk for malnutrition, at a dose of 1 liter infused over 12 hours for 7 to 10 consecutive days. A prospective, multicentre, randomized, open-label, non-inferiority, controlled phase III B trial carried out in parallel groups: subcutaneous versus peripheral intravenous administration.EUCTR2007-006153-31-FRBaxter R and D Europe SCR120
Completed
Phase 3
The saftey and efficacy of intradermal injection of type A butulinum toxin in chemotherapy induced peripheral neuropathyChemotherapy induced neuropathy.IRCT20200425047202N1Shahid Beheshti University of Medical Sciences40